2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

FDA Approved RSV treatments | iPharmaCneter

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

FDA Approved diabetic treatments | 2023 |

FDA News and Updates | US Pharma News | iPharmaCenter

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Gilead’s Trodelvy approved for triple-negative breast cancer in US